|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.341 EUR | -1.01% |
|
+0.41% | +16.77% |
| 13/01 | Evotec says Michael Kaufman holds 5.03% of total voting rights and instruments in Evotec | RE |
| 08/01 | Evotec Receives Gates Foundation Grant to Deploy AI in Optimizing Monoclonal Antibodies | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 132.38Cr | - | ||||
| 4.9TCr | |||||
| 4.11TCr | |||||
| 3.84TCr | |||||
| 3.16TCr | |||||
| 2.34TCr | - | - | - | - | - |
- Stock Market
- Equities
- EVT Stock
- Charts Evotec SE
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition